NLS Pharmaceutics Ltd. - Pangali EV/EBITDA NLSP

NLS Pharmaceutics AG (NLSP) drug distribution relies on strictly controlled transportation to eliminate theft. Growth prospects are tied to upcoming clinical trial stages for insomnia treatments, while investors have already priced in the current shortage of medications. The market dynamics reflected in the quotes on GURU.Markets show an EV/EBITDA of , confirming the potential for pricing power driven by the unique stimulant Mazindol for narcolepsy therapy.

NLS Pharmaceutics AG (NLSP) is investing in the development of innovative drugs for the treatment of ADHD and narcolepsy, which requires significant capital expenditures. The EV/EBITDA multiple trend compares the total market value of the business, including debt, to its operating profit before interest, taxes, depreciation, and amortization. The stability of this chart confirms a resilient valuation, although a stagnant indicator may signal an undervaluation of the R&D assets' potential.